# China NMPA Drug Inspection - Sichuan Tongchuang Kangneng Pharmaceutical Co., Ltd. - Privet

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/sichuan-tongchuang-kangneng-pharmaceutical-co-ltd/4aa7c7da-1537-423f-a9d0-7ead099cf129/
Source feed: China

> China NMPA drug inspection for Sichuan Tongchuang Kangneng Pharmaceutical Co., Ltd. published July 17, 2023. Drug: Privet. On July 17, 2023, the National Medical Products Administration (NMPA) issued Announcement No. 30, reporting that 49 batc

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 30 of 2023 from the National Medical Products Administration regarding 49 batches of drugs that did not meet the requirements.
- Company Name: Sichuan Tongchuang Kangneng Pharmaceutical Co., Ltd.
- Publication Date: 2023-07-17
- Drug Name: Privet
- Inspection Finding: [Inspection] (Moisture content) does not meet regulations.
- Action Taken: Risk control measures such as suspending sales and use and recalling products should be implemented. Investigations should be conducted into the reasons for non-compliance and rectification should be carried out effectively. Cases should be filed for investigation, and the results of the investigation should be made public in accordance with regulations.
- Summary: On July 17, 2023, the National Medical Products Administration (NMPA) issued Announcement No. 30, reporting that 49 batches of drugs failed to meet quality standards during recent testing. A significant number of violations were attributed to Beijing Langdi Pharmaceutical Co., Ltd. and its contract manufacturer, Shanxi Zhendong Pharmaceutical Co., Ltd., particularly regarding Calcium Carbonate D3 granules and tablets that failed 'content determination' tests for Vitamin D3 levels. Other cited companies include Hebei Jinniu Yuanda Pharmaceutical, Changchun Xin’an Pharmaceutical, and several Traditional Chinese Medicine suppliers such as Anguo Runde Pharmaceutical. The inspections identified various quality issues, including inaccurate ingredient concentrations, poor dissolution rates, excessive moisture content, and failures in physical adhesion and weight consistency. These findings were evaluated against the regulatory framework of the Drug Administration Law of the People's Republic of China and the 2020 edition of the Chinese Pharmacopoeia. In response, the NMPA has ordered immediate risk control measures, including the suspension of sales and use, alongside a total recall of the non-compliant batches. The involved enterprises must investigate the root causes of these failures and implement corrective actions, while provincial authorities conduct further legal investigations into the suspected misconduct.

Company: https://www.globalkeysolutions.net/companies/sichuan-tongchuang-kangneng-pharmaceutical-co-ltd/3697dc91-5ac7-41dc-97ab-0e02ab91fe06/